RASAYANA™ TECHNOLOGY PLATFORM Rasayana™ is a highly customizable family of drug delivery vehicles that can easily be customized to carry a wide range of therapeutics, MRI contrast agents and targeting agents in the form of Target Specific Delivery Vehicles (TSDV™).

Major Established Features of Rasayana™

In vitro and in vivo testing indicate that the TSDV™, the NanoBindi™ based delivery vehicles can be customized with the following properties: 

·         Increased solubility – TSDV™ can enhance significantly and modulate the aqueous solubility of drugs that are not themselves soluble at physiological conditions.

·         Increased circulation half-life – Rasayana™ can be used to increase the effective size of a small molecule drug above the threshold for passive glomerular filtration (ca. 35nm), thereby reducing kidney clearance and increasing circulation time in the bloodstream. 

·         Tumor accumulation –The nanoscale size of TSDV™ particles results in an increase of the concentration of a drug in tumors relative to other organs and tissues by way of active targeting based on its ligand-receptor binding functionality.

·         Improved pharmacokinetics and pharmacodynamics of drugs – TSDV™ can protect therapeutic payloads and minimize or prevent non-specific interactions with blood elements, organs and tissues until it arrives at the desired target organ, tissue or cell type, and through various triggered sensors, can control the release of the payload over time or in response to specific external non-invasive signals or physiological conditions, thereby enhancing the PK/PD properties of the drug. 

·         Stealthy to the immune system– The immunologically inert nature of the TSDV™ allows for repeat dosing without the risk of host immune reactions.

·         Non-toxic– TSDV™ has been shown to be non-toxic in in vitro testing with human cell cultures and in in vivo tests in animals, and the fully formulated TSDV™-therapeutic particles produced no toxicity in mice at doses, once properly converted to human scale, well above levels expected to be used in human therapeutics.

·         Stable under physiological conditions– NanoBindi particles have been shown to be stable under physiological conditions.

·         Efficient in targeted delivery– Chikujee Therapeutics and its partners have demonstrated successful delivery of functional therapeutics directly to tumor cells.

·         Fully integrated system– Chikujee Therapeutics has made significant advances in the design and development of a delivery system that bypasses the extra-cellular barriers to therapeutic delivery. The company believes its delivery technologies facilitate safe and effective site-directed intracellular delivery of small molecules, proteins and peptides. 

Additional Features of Rasayana™

In contrast to passive drug carriers or excipients, BOSH™ polymeric shells can be made to respond to biological mechanisms and micro-environmental conditions such as:

·         Biodegradable Polymers- TSDV™ can be synthesized with biodegradable linkages between other biodegradable co-monomers, allowing the safe delivery of longer polymers to increase circulation half-life and target tissue accumulation.  Over time, the BOSH™ polymer as well as BOSH™ and other suitable biodegradable monomer combinations, breaks down into smaller component parts that are small enough to be eliminated through normal body clearance mechanisms including, renal clearance.

·         Temperature-Sensitive TSDV™-  Reactive group modifications on the BOSH™ shell can facilitate drug release in response to external non-invasive signals, allowing, for example, intracellular release of the drug payload.

·         Targeted Therapeutics-  By attaching a cell specific targeting agent on one of the reactive groups on TSDV™, and with specific binding to surface receptors on targeted cells, we can ensure specific uptake into target cells – an objective that we have demonstrated and verified in animal models.

·         Multiple Formulations- TSDV™ can be administered intravenously, and can also be synthesized as a gel for topical administration, as a solid or semi-solid for use as a continual-release implant, or in particulate form for inhalable therapies. 

·         Scalable Synthesis- TSDV™ was designed and developed taking into consideration the need for ease of manufacturing scale-up and commercialization at a reasonable cost. We have achieved manufacturing scale-up of the TSDV™ polymer delivery system.